The estimated Net Worth of Advisors, Ltd.Hillhouse Inv... is at least $31 Bilhão dollars as of 13 June 2023. Advisors Inv owns over 1,198,128 units of BeiGene Ltd stock worth over $30,170,852,087 and over the last 2 years Advisors sold BGNE stock worth over $823,494,461.
Advisors has made over 2 trades of the BeiGene Ltd stock since 2023, according to the Form 4 filled with the SEC. Most recently Advisors sold 1,198,128 units of BGNE stock worth $226,302,417 on 13 June 2023.
The largest trade Advisors's ever made was selling 2,956,689 units of BeiGene Ltd stock on 8 June 2023 worth over $597,192,044. On average, Advisors trades about 1,384,939 units every 2 days since 2022. As of 13 June 2023 Advisors still owns at least 142,888,241 units of BeiGene Ltd stock.
You can see the complete history of Advisors Inv stock trades at the bottom of the page.
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., eBros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: